• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4676884)   Today's Articles (0)
For: Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara SI, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. [PMID: 17625570 DOI: 10.1038/nature05945] [Citation(s) in RCA: 4029] [Impact Index Per Article: 223.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2007] [Accepted: 05/17/2007] [Indexed: 02/07/2023]
Number Cited by Other Article(s)
1
Gemmell JS, Lucke-Wold B. Traditional Chinese medicine and modern technology: Network pharmacology and omics sequencing in gastric cancer. World J Gastrointest Oncol 2025;17:102077. [DOI: 10.4251/wjgo.v17.i3.102077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2024] [Revised: 12/10/2024] [Accepted: 01/02/2025] [Indexed: 02/14/2025]  Open
2
Chitale GG, Kulkarni SR, Bapat SA. Chimerism: A whole new perspective in gene regulation. Biochim Biophys Acta Gen Subj 2025;1869:130767. [PMID: 39855315 DOI: 10.1016/j.bbagen.2025.130767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2024] [Revised: 01/10/2025] [Accepted: 01/16/2025] [Indexed: 01/27/2025]
3
Guo X, Liu Y, Wang YT, Liu K, Ding H. Combined BRAF G469A mutation and echinoderm microtubule associated protein like-4-anaplastic lymphoma kinase rearrangement with resistance: A case report and review of literature. World J Clin Oncol 2025;16:98812. [DOI: 10.5306/wjco.v16.i2.98812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2024] [Revised: 10/13/2024] [Accepted: 10/24/2024] [Indexed: 12/11/2024]  Open
4
Sikkema BJ, Baart SJ, Paats MS, Smit EF, Schols AMWJ, Mathijssen RHJ, van Rossum EFC, Dingemans AMC. Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials. J Clin Oncol 2025;43:641-650. [PMID: 39661917 DOI: 10.1200/jco-24-01579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2024] [Revised: 09/30/2024] [Accepted: 10/31/2024] [Indexed: 12/13/2024]  Open
5
Vincoff S, Goel S, Kholina K, Pulugurta R, Vure P, Chatterjee P. FusOn-pLM: a fusion oncoprotein-specific language model via adjusted rate masking. Nat Commun 2025;16:1436. [PMID: 39920196 PMCID: PMC11806025 DOI: 10.1038/s41467-025-56745-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2024] [Accepted: 01/24/2025] [Indexed: 02/09/2025]  Open
6
Wang M, Liu H, Zhang R, Li R, Qin X, Ning F, Tian L. Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review. J Cancer Res Clin Oncol 2025;151:62. [PMID: 39909915 PMCID: PMC11799027 DOI: 10.1007/s00432-025-06091-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2024] [Accepted: 01/09/2025] [Indexed: 02/07/2025]
7
Zhao H, Huang S, Wu J, Lu Y, Zou Y, Zeng H, Li C, Wang J, Zhang X, Duan S, Liang W. Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis. Front Immunol 2025;16:1515027. [PMID: 39981238 PMCID: PMC11839650 DOI: 10.3389/fimmu.2025.1515027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2024] [Accepted: 01/20/2025] [Indexed: 02/22/2025]  Open
8
Camidge DR, Sugawara S, Kondo M, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Kudou K, Asato T, Hupf B, Vranceanu F, Fram RJ, Ohe Y, Popat S. Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials. Lung Cancer 2025;201:108424. [PMID: 39923717 DOI: 10.1016/j.lungcan.2025.108424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2024] [Revised: 01/29/2025] [Accepted: 02/03/2025] [Indexed: 02/11/2025]
9
Utsumi T, Mizuta H, Seto Y, Uchibori K, Nishio M, Okamoto I, Katayama R. AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts. Cancer Sci 2025. [PMID: 39904499 DOI: 10.1111/cas.70006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2024] [Revised: 01/10/2025] [Accepted: 01/22/2025] [Indexed: 02/06/2025]  Open
10
Poei D, Ali S, Thomas JS, Nieva JJ, Hsu RC. Real-World Incidence of Anaplastic Lymphoma Kinase Alterations in Hispanics with Non-Small Cell Lung Cancer at a Large Academic Institution in Los Angeles. CANCER RESEARCH COMMUNICATIONS 2025;5:277-286. [PMID: 39807831 PMCID: PMC11808653 DOI: 10.1158/2767-9764.crc-24-0504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/27/2024] [Revised: 12/09/2024] [Accepted: 01/10/2025] [Indexed: 01/16/2025]
11
Ka M, Matsumoto Y, Ando T, Hinata M, Xi Q, Sugiura Y, Iida T, Nakagawa N, Tokunaga M, Watanabe K, Kawakami M, Ushiku T, Sato M, Oda K, Kage H. Integrin-α5 expression and its role in non-small cell lung cancer progression. Cancer Sci 2025;116:406-419. [PMID: 39581761 PMCID: PMC11786322 DOI: 10.1111/cas.16416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2024] [Revised: 11/12/2024] [Accepted: 11/14/2024] [Indexed: 11/26/2024]  Open
12
Wang S, Wang Y, Wu X, Yang L, Zhang X. Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy. World J Surg Oncol 2025;23:34. [PMID: 39893475 PMCID: PMC11787757 DOI: 10.1186/s12957-025-03687-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2024] [Accepted: 01/24/2025] [Indexed: 02/04/2025]  Open
13
Luo W, Zheng J, Hei M, Jiang Y, Su B. Superficial ALK-rearranged myxoid spindle cell neoplasms: Clinicopathologic and molecular analysis of two cases and a review of the literature. Ann Diagn Pathol 2025;74:152395. [PMID: 39550857 DOI: 10.1016/j.anndiagpath.2024.152395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2024] [Revised: 11/05/2024] [Accepted: 11/05/2024] [Indexed: 11/19/2024]
14
Apsel Winger B, Dowd CF, Shimano KA, Devine WP, Mathes E, Frieden I, Schaefer C, Kothari A. Effective Use of ALK Inhibitors in EML4::ALK-Positive Lymphatic Malformations. Pediatr Blood Cancer 2025;72:e31441. [PMID: 39529238 DOI: 10.1002/pbc.31441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2024] [Revised: 10/08/2024] [Accepted: 10/27/2024] [Indexed: 11/16/2024]
15
Graciotti M, Kandalaft LE. Vaccines for cancer prevention: exploring opportunities and navigating challenges. Nat Rev Drug Discov 2025;24:134-150. [PMID: 39622986 DOI: 10.1038/s41573-024-01081-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/24/2024] [Indexed: 02/06/2025]
16
Shiraishi N, Takahama T, Sakai K, Tanaka K, Nakagawa Y, Kanemura H, Nakayama T, Kawanaka Y, Kurosaki T, Suzuki S, Iwasa T, Tanizaki J, Inagaki C, Yonesaka K, Fukuoka K, Mitsudomi T, Nishio K, Hayashi H, Nakagawa K. Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing. Thorac Cancer 2025;16:e70007. [PMID: 39947926 PMCID: PMC11825211 DOI: 10.1111/1759-7714.70007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2024] [Revised: 01/16/2025] [Accepted: 01/18/2025] [Indexed: 02/16/2025]  Open
17
Waliany S, Lin JJ, Gainor JF. Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer. Trends Cancer 2025:S2405-8033(25)00006-8. [PMID: 39890507 DOI: 10.1016/j.trecan.2025.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2024] [Revised: 12/21/2024] [Accepted: 01/10/2025] [Indexed: 02/03/2025]
18
Schneider JL, Kurmi K, Dai Y, Dhiman I, Joshi S, Gassaway BM, Johnson CW, Jones N, Li Z, Joschko CP, Fujino T, Paulo JA, Yoda S, Baquer G, Ruiz D, Stopka SA, Kelley L, Do A, Mino-Kenudson M, Sequist LV, Lin JJ, Agar NYR, Gygi SP, Haigis KM, Hata AN, Haigis MC. GUK1 activation is a metabolic liability in lung cancer. Cell 2025:S0092-8674(25)00093-5. [PMID: 39919745 DOI: 10.1016/j.cell.2025.01.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 08/14/2024] [Accepted: 01/15/2025] [Indexed: 02/09/2025]
19
Borkhataria CH, Sharma S, Vaja P, Tank C, Mori D, Patel K, Kyada A. Quality management, ethical considerations, and emerging challenges in genomics and biobanking: A comprehensive review. Clin Chim Acta 2025;569:120161. [PMID: 39864572 DOI: 10.1016/j.cca.2025.120161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2024] [Revised: 01/23/2025] [Accepted: 01/23/2025] [Indexed: 01/28/2025]
20
Heo Y, Kim WJ, Cho YJ, Jung JW, Kim NS, Choi IY. Advances in cancer genomics and precision oncology. Genes Genomics 2025:10.1007/s13258-024-01614-7. [PMID: 39849190 DOI: 10.1007/s13258-024-01614-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2024] [Accepted: 12/27/2024] [Indexed: 01/25/2025]
21
Yi GZ, Zhang HY, Que TS, Qu SQ, Li ZY, Qi ST, Feng WY, Huang GL. Identification of the clinical and genetic characteristics of gliomas with gene fusions by integrated genomic and transcriptomic analysis. Eur J Med Res 2025;30:49. [PMID: 39849652 PMCID: PMC11755825 DOI: 10.1186/s40001-025-02306-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2023] [Accepted: 01/16/2025] [Indexed: 01/25/2025]  Open
22
Mina SA, Shanshal M, Leventakos K, Parikh K. Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC). Cancers (Basel) 2025;17:353. [PMID: 39941723 PMCID: PMC11816067 DOI: 10.3390/cancers17030353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2024] [Revised: 01/13/2025] [Accepted: 01/18/2025] [Indexed: 02/16/2025]  Open
23
Watanabe T, Kidoguchi K, Kimura S. Treating Hematological Malignancies With OR-2100, an Orally Bioavailable Prodrug of Decitabine. Cancer Sci 2025. [PMID: 39837580 DOI: 10.1111/cas.16452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2024] [Revised: 12/06/2024] [Accepted: 01/06/2025] [Indexed: 01/23/2025]  Open
24
Melosky B, Juergens RA, Banerji S, Sacher A, Wheatley-Price P, Snow S, Tsao MS, Leighl NB, Martins I, Cheema P, Liu G, Chu QSC. The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer. Ther Adv Med Oncol 2025;17:17588359241308784. [PMID: 39776537 PMCID: PMC11705342 DOI: 10.1177/17588359241308784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2024] [Accepted: 12/05/2024] [Indexed: 01/11/2025]  Open
25
Andrijanova A, Bugovecka L, Isajevs S, Erts D, Malinovskis U, Liepins A. Machine Learning for Lung Cancer Subtype Classification: Combining Clinical, Histopathological, and Biophysical Features. Diagnostics (Basel) 2025;15:127. [PMID: 39857011 PMCID: PMC11764335 DOI: 10.3390/diagnostics15020127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2024] [Revised: 12/16/2024] [Accepted: 12/20/2024] [Indexed: 01/27/2025]  Open
26
Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC. J Thorac Oncol 2025;20:109-118. [PMID: 39260522 DOI: 10.1016/j.jtho.2024.09.1379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2024] [Revised: 08/19/2024] [Accepted: 09/01/2024] [Indexed: 09/13/2024]
27
Atiq MA, Balan J, Blackburn PR, Gross JM, Voss JS, Jin L, Fadra N, Davila JI, Pitel BA, Siqueira Parrilha Terra SB, Minn KT, Jackson RA, Hofich CD, Willkomm KS, Peterson BJ, Clausen SN, Rumilla KM, Gupta S, Lo YC, Ida CM, Molligan JF, Thangaiah JJ, Petersen MJ, Sukov WR, Guo R, Giannini C, Schoolmeester JK, Fritchie K, Inwards CY, Folpe AL, Oliveira AM, Torres-Mora J, Kipp BR, Halling KC. SARCP, a Clinical Next-Generation Sequencing Assay for the Detection of Gene Fusions in Sarcomas: A Description of the First 652 Cases. J Mol Diagn 2025;27:74-95. [PMID: 39521244 DOI: 10.1016/j.jmoldx.2024.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 10/11/2024] [Accepted: 10/23/2024] [Indexed: 11/16/2024]  Open
28
Du Y, Semghouli A, Wang Q, Mei H, Kiss L, Baecker D, Soloshonok VA, Han J. FDA-approved drugs featuring macrocycles or medium-sized rings. Arch Pharm (Weinheim) 2025;358:e2400890. [PMID: 39865335 PMCID: PMC11771699 DOI: 10.1002/ardp.202400890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2024] [Revised: 12/20/2024] [Accepted: 12/22/2024] [Indexed: 01/28/2025]
29
Athanasiou E, Papageorgiou S, Dafni MF, Kelesis I, Vasileiou M, Tatsiou T, Kouveloglou V, Kanatas P, Stouras I, Gatsis A, Agiassoti VT, Nasimpian P, Dafnoudis D, Degaita K, Verras GI, Alexiou A, Papadakis M, Kamal MA. The use of Isoflavones as Lung Cancer Chemoprevention Agents and their Implications in Treatment through Radio Sensitization. Curr Med Chem 2025;32:214-237. [PMID: 38369709 DOI: 10.2174/0109298673278897231229121524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 11/07/2023] [Accepted: 11/21/2023] [Indexed: 02/20/2024]
30
Shimomura Y, Mizutani M, Yoshida H, Ihara Y, Shintani A. Immunotherapy Following Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients with Anaplastic Lymphoma Kinase‑Positive Non‑small Cell Lung Cancer in Japan. Target Oncol 2025;20:171-180. [PMID: 39607635 DOI: 10.1007/s11523-024-01116-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/08/2024] [Indexed: 11/29/2024]
31
Li Q, Cai T, Zheng X, Zhang S, Li C, Tang H, Yu Z, Zhou J. EML4-ALK-Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review. Clin Case Rep 2025;13:e70043. [PMID: 39780907 PMCID: PMC11707256 DOI: 10.1002/ccr3.70043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2024] [Accepted: 12/16/2024] [Indexed: 01/11/2025]  Open
32
Gardić N, Lovrenski A, Sekeruš V, Kašiković Lečić S, Bijelović M, Lakić T, Ilić A, Zarić B, Glumac S. Cytomorphological and histomorphological features of lung adenocarcinoma with epidermal growth factor receptor mutation and anaplastic lymphoma kinase gene rearrangement. Oncol Lett 2025;29:40. [PMID: 39530007 PMCID: PMC11552093 DOI: 10.3892/ol.2024.14786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2024] [Accepted: 10/16/2024] [Indexed: 11/16/2024]  Open
33
Bearz A, Bertoli E, Stanzione B, De Carlo E, Del Conte A, Bortolot M, Torresan S, Berto E, Da Ros V, Pelin GM, Fassetta K, Rossetto S, Spina M. EML4-ALK: Update on ALK Inhibitors. Int J Mol Sci 2025;26:308. [PMID: 39796163 PMCID: PMC11719670 DOI: 10.3390/ijms26010308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2024] [Revised: 12/29/2024] [Accepted: 12/30/2024] [Indexed: 01/13/2025]  Open
34
Chayab L, Leighl NB, Tadrous M, Warren CM, Wong WWL. Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada. Curr Oncol 2024;32:13. [PMID: 39851929 PMCID: PMC11764221 DOI: 10.3390/curroncol32010013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2024] [Revised: 12/21/2024] [Accepted: 12/24/2024] [Indexed: 01/30/2025]  Open
35
Sampson J, Ju HM, Zhang N, Yeoh S, Choi J, Bayliss R. Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer. Cell Death Dis 2024;15:912. [PMID: 39695132 DOI: 10.1038/s41419-024-07272-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2024] [Revised: 11/22/2024] [Accepted: 11/29/2024] [Indexed: 12/20/2024]
36
Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Su KY, Chang YL, Wu CT, Hsu CC, Liu YN, Peng GR, Kangartaputra AA, Yu SH, Liao BC, Hsu WH, Lee JH, Lin CC, Shih JY, Chih-Hsin Yang J, Yu CJ. PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study. J Formos Med Assoc 2024:S0929-6646(24)00579-5. [PMID: 39694766 DOI: 10.1016/j.jfma.2024.12.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2024] [Revised: 10/10/2024] [Accepted: 12/13/2024] [Indexed: 12/20/2024]  Open
37
Huang L, Kong W, Luo Y, Xie H, Liu J, Zhang X, Zhang G. Predicting epidermal growth factor receptor mutation status of lung adenocarcinoma based on PET/CT images using deep learning. Front Oncol 2024;14:1458374. [PMID: 39735601 PMCID: PMC11671303 DOI: 10.3389/fonc.2024.1458374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2024] [Accepted: 11/20/2024] [Indexed: 12/31/2024]  Open
38
Wu Q, Nandi D, Sharma D. TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond. Cancer Metastasis Rev 2024;44:16. [PMID: 39644332 PMCID: PMC11625080 DOI: 10.1007/s10555-024-10226-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2024] [Accepted: 10/16/2024] [Indexed: 12/09/2024]
39
Zhou H, Hu M, Jie H, Li Y, Tang K, Pan L, Liu C, Liu Z, Chen W, Chen Y, Luo Y, Gong Y, Xie Y. Discovery of orally bioavailable ALK PROTACs based ceritinib against ALK positive cancers. Eur J Med Chem 2024;279:116827. [PMID: 39288596 DOI: 10.1016/j.ejmech.2024.116827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2024] [Revised: 08/30/2024] [Accepted: 08/31/2024] [Indexed: 09/19/2024]
40
Chen P, Zheng X, Li C, Li J, Yang C, Feng Y, Cheng B, Liang H, Liu Z, Zhao Y, Xiong S, Li F, Zhong R, Zhan S, Wang H, Xiang Y, Fu W, Ye W, Jiang B, Fan X, Liu J, He J, Liang W. Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC. BMJ Open Respir Res 2024;11:e002571. [PMID: 39632102 PMCID: PMC11624786 DOI: 10.1136/bmjresp-2024-002571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2024] [Accepted: 10/24/2024] [Indexed: 12/07/2024]  Open
41
Podder V, Ranjan T, Gowda M, Camacho AM, Ahluwalia MS. Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review. Curr Neurol Neurosci Rep 2024;25:6. [PMID: 39625633 DOI: 10.1007/s11910-024-01388-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/19/2024] [Indexed: 12/17/2024]
42
Lin JJ, Horan JC, Tangpeerachaikul A, Swalduz A, Valdivia A, Johnson ML, Besse B, Camidge DR, Fujino T, Yoda S, Nguyen-Phuong L, Mizuta H, Bigot L, Nobre C, Lee JB, Yu MR, Mente S, Sun Y, Kohl NE, Porter JR, Shair MD, Zhu VW, Felip E, Cho BC, Friboulet L, Hata AN, Pelish HE, Drilon A. NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer Discov 2024;14:2367-2386. [PMID: 39269178 PMCID: PMC11609626 DOI: 10.1158/2159-8290.cd-24-0231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2024] [Revised: 05/25/2024] [Accepted: 08/06/2024] [Indexed: 09/15/2024]
43
Du M, Liu C, Chen L, Li Z, Zhang S, Meng R. Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome. THE CLINICAL RESPIRATORY JOURNAL 2024;18:e70041. [PMID: 39681089 DOI: 10.1111/crj.70041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/06/2024] [Revised: 11/11/2024] [Accepted: 11/20/2024] [Indexed: 12/18/2024]
44
Nobuoka M, Mukawa T, Iwaya M, Shigeto S, Minagawa T, Uehara T, Akiyama Y. SMARCB1-deficient renal medullary carcinoma with an EML4::ALK fusion gene in a Japanese woman. Pathol Int 2024;74:704-707. [PMID: 39503184 DOI: 10.1111/pin.13494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2024] [Revised: 10/22/2024] [Accepted: 10/24/2024] [Indexed: 12/13/2024]
45
Wang KL, Yeh TY, Hsu PC, Wong TH, Liu JR, Chern JW, Lin MH, Yu CW. Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer. J Enzyme Inhib Med Chem 2024;39:2318645. [PMID: 38465731 DOI: 10.1080/14756366.2024.2318645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Accepted: 01/11/2024] [Indexed: 03/12/2024]  Open
46
Zhang X, Tong J, Wang T, Wang Z, Gu S, Xu L, Hou T, Pan P. In-depth theoretical modeling to explore the mechanism of TPX-0131 overcoming lorlatinib resistance to ALKL1196M/G1202R mutation. Comput Biol Med 2024;183:109265. [PMID: 39405725 DOI: 10.1016/j.compbiomed.2024.109265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2024] [Revised: 09/19/2024] [Accepted: 10/07/2024] [Indexed: 11/20/2024]
47
Mizuno Y, Tada Y, Uehara T, Yamashita S, Murai H. A Case of Small-Cell Lung Cancer With Novel Anaplastic Lymphoma Kinase Gene Rearrangement That Developed Intradural Extramedullary Spinal Metastases With Myelitis. Cureus 2024;16:e75369. [PMID: 39781173 PMCID: PMC11707969 DOI: 10.7759/cureus.75369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/09/2024] [Indexed: 01/12/2025]  Open
48
Bae K, Kim DE, Kim JH, Lee JY, Yoon KA. Oncogenic fusion of CD63-BCAR4 contributes cancer stem cell-like properties via ALDH1 activity. Mol Carcinog 2024;63:2282-2290. [PMID: 39136580 DOI: 10.1002/mc.23808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2024] [Revised: 06/13/2024] [Accepted: 07/30/2024] [Indexed: 11/16/2024]
49
Park SM, Haam K, Heo H, Kim D, Kim MJ, Jung HJ, Cha S, Kim M, Lee H. Integrative transcriptomic analysis identifies emetine as a promising candidate for overcoming acquired resistance to ALK inhibitors in lung cancer. Mol Oncol 2024. [PMID: 39540457 DOI: 10.1002/1878-0261.13738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2024] [Revised: 08/02/2024] [Accepted: 09/10/2024] [Indexed: 11/16/2024]  Open
50
Qu D, Yan A. Classification models and SAR analysis of anaplastic lymphoma kinase (ALK) inhibitors using machine learning algorithms with two data division methods. Mol Divers 2024:10.1007/s11030-024-10990-x. [PMID: 39531134 DOI: 10.1007/s11030-024-10990-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2024] [Accepted: 09/06/2024] [Indexed: 11/16/2024]
PrevPage 1 of 81 123458081Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Excel